Evaluation of a hybrid capture–based pan-cancer panel for analysis of treatment stratifying oncogenic aberrations and processes by Kroeze, Leonie I. et al.
 
 
University of Birmingham
Evaluation of a hybrid capture–based pan-cancer
panel for analysis of treatment stratifying oncogenic
aberrations and processes
Kroeze, Leonie I.; De Voer, Richarda M.; Kamping, Eveline J.; Von Rhein, Daniel; Jansen,
Erik A.m.; Hermsen, Mandy J.w.; Barberis, Massimo C.p.; Botling, Johan; Garrido-martin, Eva
M.; Haller, Florian; Lacroix, Ludovic; Maes, Brigitte; Merkelbach-bruse, Sabine; Pestinger,
Valerie; Pfarr, Nicole; Stenzinger, Albrecht; Van Den Heuvel, Michel M.; Grünberg, Katrien;
Ligtenberg, Marjolijn J.l.
DOI:
10.1016/j.jmoldx.2020.02.009
License:
Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Kroeze, LI, De Voer, RM, Kamping, EJ, Von Rhein, D, Jansen, EAM, Hermsen, MJW, Barberis, MCP, Botling, J,
Garrido-martin, EM, Haller, F, Lacroix, L, Maes, B, Merkelbach-bruse, S, Pestinger, V, Pfarr, N, Stenzinger, A,
Van Den Heuvel, MM, Grünberg, K & Ligtenberg, MJL 2020, 'Evaluation of a hybrid capture–based pan-cancer
panel for analysis of treatment stratifying oncogenic aberrations and processes', Journal of Molecular
Diagnostics, vol. 22, no. 6, pp. 757-769. https://doi.org/10.1016/j.jmoldx.2020.02.009
Link to publication on Research at Birmingham portal
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 14. Jun. 2020
The Journal of Molecular Diagnostics, Vol. 22, No. 6, June 2020jmd.amjpathol.orgEvaluation of a Hybrid CaptureeBased
Pan-Cancer Panel for Analysis of Treatment
Stratifying Oncogenic Aberrations and Processes
Leonie I. Kroeze,* Richarda M. de Voer,y Eveline J. Kamping,y Daniel von Rhein,y Erik A.M. Jansen,y Mandy J.W. Hermsen,*
Massimo C.P. Barberis,z Johan Botling,x Eva M. Garrido-Martin,{ Florian Haller,k Ludovic Lacroix,** Brigitte Maes,yy
Sabine Merkelbach-Bruse,zz Valerie Pestinger,xx Nicole Pfarr,{{ Albrecht Stenzinger,kk Michel M. van den Heuvel,***
Katrien Grünberg,* and Marjolijn J.L. Ligtenberg*yFrom the Departments of Pathology* and Human Genetics,y Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen,
the Netherlands; the Division of Pathology and Laboratory Medicine,z European Institute of Oncology, Milan, Italy; the Department of Immunology, Genetics
and Pathology,x Science for Life Laboratory, Uppsala University, Uppsala, Sweden; the Instituto de Investigación iþ12,{ University Hospital 12 de Octubre,
Spanish National Center for Cancer Research and Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain; the Institute of Pathology,k
University Hospital Erlangen, Erlangen, Germany; the Department of Medical Biology and Pathology,** Institut Gustave Roussy, Villejuif, France; the
Laboratory for Molecular Diagnostics,yy Department of Clinical Biology, Jessa Hospital, Hasselt, Belgium; the Institute of Pathology,zz University Hospital
Cologne, Cologne, Germany; the Institute of Cancer and Genomic Sciences,xx University of Birmingham, Birmingham, United Kingdom; the Institute of
Pathology,{{ Technical University of Munich, School of Medicine, Munich, Germany; the Institute of Pathology,kk Heidelberg University Hospital,
Heidelberg, Germany; and the Department of Pulmonology,*** Radboud University Medical Center, Nijmegen, the NetherlandsAccepted for publicationt
I
A
o
N
C
T
hFebruary 26, 2020.
Address correspondence to
Marjolijn J.L. Ligtenberg, Ph.D.,
Laboratory of Tumor Genetics,
Departments of Pathology and
Human Genetics, Radboud Uni-
versity Medical Center, P. O. Box
9101, 6500 HB Nijmegen, the
Netherlands.
E-mail: marjolijn.ligtenberg@
radboudumc.nl.Supported by Bristol-Myers Squibb gr
he TruSight Oncology 500 kits were
llumina.
Disclosures: Outside the submitted w
straZeneca, Bayer, Janssen Pharmac
utside the submitted work, A.S. has re
ovartis, BMS, Seattle Genomics, Illu
opyright ª 2020 Association for Molecular
his is an open access article under the CC B
ttps://doi.org/10.1016/j.jmoldx.2020.02.009Stratification of patients for targeted and immune-based therapies requires extensive genomic profiling
that enables sensitive detection of clinically relevant variants and interrogation of biomarkers, such as
tumor mutational burden (TMB) and microsatellite instability (MSI). Detection of single and multiple
nucleotide variants, copy number variants, MSI, and TMB was evaluated using a commercially available
next-generation sequencing panel containing 523 cancer-related genes (1.94 megabases). Analysis of
formalin-fixed, paraffin-embedded tissue sections and cytologic material from 45 tumor samples showed
that all previously known MSI-positive samples (nZ 7), amplifications (nZ 9), and pathogenic variants
(n Z 59) could be detected. TMB and MSI scores showed high intralaboratory and interlaboratory
reproducibility (eight samples tested in 11 laboratories). For reliable TMB analysis, 20 ng DNA was shown
to be sufficient, even for relatively poor-quality samples. A minimum of 20% neoplastic cells was required
to minimize variations in TMB values induced by chromosomal instability or tumor heterogeneity. Sub-
sequent analysis of 58 consecutive lung cancer samples in a diagnostic setting was successful and
revealed sufficient somatic mutations to generate mutational signatures in 14 cases. In conclusion, the
523-gene assay can be applied for evaluation of multiple DNA-based biomarkers relevant for treatment
selection. (J Mol Diagn 2020, 22: 757e769; https://doi.org/10.1016/j.jmoldx.2020.02.009)With the growing number and improved efficacy of targeted
therapies, and the introduction of immunotherapy, it has
become increasingly evident that comprehensive tumorant OT123-368 (M.J.L.L.). Part of
made available free of charge by
ork, M.J.L.L. has relations with
euticals, Merck, and Nimagen;
lations with Bayer, Astra-Zeneca,
mina, Thermo Fisher Scientific,
Pathology and American Society for Investiga
Y-NC-ND license (http://creativecommons.orgprofiling is needed. Drugs targeting specific mutated genes
or activated pathways are clinically available for several
indications, and many more targeted therapies are currentlyTakeda, MSD, Pfizer, and Roche; outside the submitted work, E.M.G.-M.
has been in four advisory boards for Bristol Myers Squibb, and received
honoraria from Illumina; outside the submitted work, S.M.-B. has relations
with AstraZeneca, Bristol Myers Squibb, Novartis, Roche, and Pfizer.
Professional medical writers from Illumina wrote the introduction and
Materials and Methods of the manuscript.
tive Pathology. Published by Elsevier Inc.
/licenses/by-nc-nd/4.0).
Kroeze et albeing evaluated in clinical trials. In addition, in the past
decade, many improvements have been made in the field of
immunotherapy. Currently approved immunotherapies
target the immune checkpoint proteins cytotoxic T-lympho-
cyte-associated protein 4 and/or programmed cell death pro-
tein 1 (PD-1) or its ligand, programmed cell death 1 ligand 1
(PD-L1). Although the introduction of immunotherapy has
benefitted many patients, more than half of the patients show
no clear evidence of response.1e4 Furthermore, these thera-
pies are expensive and can have serious adverse effects.5e8
PD-L1 expression is an approved predictive biomarker for
immunotherapy,9 but its analysis by immunohistochemistry
has several significant challenges, including the typical
interobserver variability in scoring and the use of different
antibodies and different staining platforms.10e12 Moreover, it
has limited predictive value as some patients with low or even
negative PD-L1 expression have been shown to benefit from
immunotherapy.13,14 The first Food and Drug
Administrationeapproved tumor typeeagnostic biomarker
for immunotherapy is microsatellite instability (MSI).
Microsatellite instability is caused by inactivation of one of
the mismatch repair genes, which results in an inability to
correct DNA replication errors and leads to a high amount of
neopeptides that may serve as targets for the immune sys-
tem.15,16 The incidence of MSI varies among cancers, but is
overall rare in most cancer types. More recently, several
studies have shown that tumor mutational burden [TMB;
number of mutations/megabase (mut/Mb)] correlates with
clinical outcome and the effectiveness of immune checkpoint
inhibitor immunotherapies17e22 and thusmay serve as a novel
biomarker. Similar to MSI, the TMB value is thought to
correlate with the efficacy of immunotherapy, because mu-
tations result in slightly modified proteins that can be recog-
nized as neoantigens by the immune system.23,24 The TMB
threshold for successful immunotherapy may differ per tumor
type.25 For lung cancer, the threshold was set at 10 mut/Mb in
the CheckMate 568.19 Several factors are associated with an
increased TMB.26 For example, environmental factors,
like UV light and tobacco use, can be responsible for an
increased mutational load in melanoma and lung cancer,
respectively.27e29 Also, MSI and mutations in exonuclease
domains ofDNApolymerase ε (POLE ) andDNApolymerase
d 1 (POLD1), involved in DNA repair, can lead to a high
TMB.29e32 In addition, the detection of mutations and
amplifications associated with resistance to targeted33,34 and
immunotherapy35 becomes increasingly important.
Because the amount of DNA available for genetic anal-
ysis is often limited, it is preferred to simultaneously assess
all major genetic biomarkers and drug targets important for
targeted as well as immune-based therapies, in one single
assay. The current article evaluates TruSight Oncology 500
(TSO500; Illumina, San Diego, CA), a next-generation
sequencing (NGS) panel containing 523 cancer-related
genes (1.94 Mb) that can be used to assess pathogenic
single-nucleotide variants (SNVs) and multiple-nucleotide
variants, copy number variants (CNVs), MSI, and TMB.758TSO500 was selected because it is a hybrid captureebased
assay evaluating >1.2 Mb of coding sequence that uses
unique molecular identifiers (UMIs) to enable sensitive
mutation detection and to reduce the background noise that
is caused by deamination artifacts in formalin-fixed mate-
rials. Detection of mutations and CNVs and the intra-
laboratory and interlaboratory reproducibility of TMB and
MSI analyses were evaluated using different amounts and
sources of input material and different neoplastic cell per-
centages. Finally, to evaluate the applicability of the
TSO500 assay in clinical practice, a consecutive series of 58
lung cancer samples was analyzed. For samples with >30
somatic SNVs, mutational signature analysis was
performed.
Materials and Methods
Sample Collection
To evaluate the performance of the TSO500 DNA assay, 45
tumor samples were selected from our routine clinical
practice on the basis of known genetic defects (including
samples with splice site mutations and large deletions or
duplications in relevant genes), amplifications (low and high
level), and MSI status. This set of tumor samples consists of
samples from different tumor types: lung (n Z 16), colon
(nZ 7), melanoma (nZ 6), bladder (nZ 4), endometrium
(n Z 2), ovary (n Z 2), prostate (n Z 2), gastrointestinal
stromal tumors (n Z 2), glioblastoma (n Z 1), larynx
(n Z 1), pancreas (n Z 1), and salivary gland (n Z 1).
Mean patient age was 66 years (range, 40 to 96 years). In
addition, 11 normal tissue samples were used in this eval-
uation phase. The mean age of these individuals was 67
years (range, 49 to 72 years). One of the control samples
was a peripheral blood sample, and the other 10 samples
were healthy tissue from colon (n Z 3), lung (n Z 3),
lymph node (n Z 3), and prostate (n Z 1). After imple-
mentation of the assay in routine diagnostics, 58 consecu-
tive lung cancer samples were analyzed.
Most samples (n Z 87) were formalin-fixed, paraffin-
embedded (FPPE) tissue samples. In addition, one blood
sample (normal control), one cerebrospinal fluid sample,
one fresh frozen tissue sample, and 24 cytologic materials
(16 embedded in agar, six Giemsa-stained tissue slides, and
two Papanicolaou-stained slides) were used. More infor-
mation about the samples used for the different analyses can
be found in Figure 1 and Supplemental Table S1. The study
was conducted in accordance with the institutional guide-
lines and regulations from Radboud University Medical
Center (Nijmegen, the Netherlands; Commissie Mensge-
bonden Onderzoek 2018-4758).
Nucleic Acid Extraction
Genomic DNA was isolated from tissue sections (generally
6  10 mm) using 5% Chelex-100 and 400 mg proteinase K,jmd.amjpathol.org - The Journal of Molecular Diagnostics
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11 normal ssues
45 tumor samples
Assay performance - all 56 samples
- Coverage -->1 sample excluded for further analysis
- Mutaon and CNV detecon
- MSI and TMB analysis
- Intralaboratory and interlaboratory* reproducibility
    
Mutaonal signature analysis - 19 tumor samples
All samples with TMB ≥ 10 mut/Mb and 
≥ 30 somac variants
Samples
    
58 consecuve 
lung cancer samples
TSO500 analysis - all 58 samples
- Mutaon and CNV detecon: samples >10% TC
- MSI analysis: samples >30% TC
- TMB analysis: samples >20% TC
Mutaonal signature analysis - 16 samples
All samples with TMB ≥ 10 mut/Mb and 
≥ 30 somac variants
Comparison immunotherapy biomarkers - 43 samples
All samples where PD-L1, MSI, and TMB could 
be evaluated
Robustness of TMB assessment - 6 tumor samples
- Effect of DNA input and quality: 1 POLE-mutated 
sample, 1 MSI-posive sample, and 1 sample without 
MSI or a POLE mutaon
- Effect of tumor cell percentage: 2 MSI-high and 1 UV-
  induced melanoma sample  
Figure 1 Study outline. In the first phase of the study, the assay
performance, robustness of tumor mutational burden (TMB) assessment,
and the possibility to perform mutational signature analysis were evalu-
ated. Subsequently, the applicability of the assay in routine diagnostics
was evaluated in a consecutive series of 58 lung cancer specimens that
required molecular diagnostic evaluation. Laboratories indicated by the
asterisk can be found in the author affiliations. CNV, copy number variant;
MSI, microsatellite instability; mut, mutation; PD-L1, programmed cell
death 1 ligand 1; TC, tumor cell percentage; TSO500, TruSight
Oncology 500.
Optimization of TMB Assessmentfollowed by purification using the QIAamp DNA Micro Kit
(Qiagen, Venlo, the Netherlands). DNA concentrations were
measured using the Qubit Broad Range kit (Thermo Fisher
Scientific, Waltham, MA). Subsequently, 40 ng DNA was
used as input for the library preparation. A DNA integrity
number (DIN), a measure for the size of the DNA fragments
and consequently the DNA quality, was determined using
the Genomic DNA ScreenTape (Agilent Technologies,
Santa Clara, CA) on an Agilent 2200 TapeStation system
(Agilent Technologies). During the verification phase, it was
observed that a more accurate DNA input amount could be
obtained when the DNA was first diluted to 10 ng/mL using
0.1 Tris-EDTA, after which the concentration was
remeasured using the Qubit High Sensitivity kit (Thermo
Fisher Scientific). In addition, purification using the
QIAamp DNA Micro Kit turned out not to be required.
These two modifications were applied before analyzing 58
consecutive lung cancer samples in routine diagnostics.
TSO500 Library Preparation for Sequencing
Library preparation was performed using the hybrid
captureebased TSO500 library preparation kit following the
manufacturer’s protocol. The TSO500 assay contains probes
for 523 genes (Supplemental Table S2) and makes use of
UMIs to analyze the number of individual DNA molecules
sequenced at every position (unique coverage). Briefly,
DNA was fragmented using a Covaris S2 (Covaris,
Woburn, MA) to generate DNA fragments of 90 to 250 bp,
with a target peak at approximately 180 bp. Samples next
underwent end repair and A-tailing, before ligation of UMIs
and amplification to add index sequences for sample mul-
tiplexing. Two hybridization/capture steps were performed.
For the first hybridization, a pool of oligonucleotides spe-
cific to the 523 genes targeted by the TSO500 was hy-
bridized to the prepared DNA libraries overnight. Next,
streptavidin magnetic beads were used to capture probes
hybridized to the DNA regions of interest. A second hy-
bridization using the same probe set was performed to
ensure high specificity of the captured regions. Next, the
enriched libraries were amplified by PCR before purification
using sample purification beads. Libraries were quantified
and then normalized to ensure a uniform library represen-
tation. Finally, the libraries were pooled, denatured, and
diluted to the appropriate loading concentration.
Sequencing and Data Analysis
Libraries were sequenced on a NextSeq 500 (Illumina), with
eight to 10 libraries sequenced per run (NextSeq high
output). The sequence data were processed and analyzed by
the TruSight Oncology 500 Local App version 1.3 (Illu-
mina). UMIs are used in the analysis to determine the
unique coverage at each position and to reduce the back-
ground noise that is caused by sequencing and deamination
artifacts in formalin-fixed material. The software produces aThe Journal of Molecular Diagnostics - jmd.amjpathol.orgreport including total and nonsynonymous mutations per
Mb scores for TMB, the number and percentage of unstable
sites for MSI, and quality parameters like median unique
exon coverage and insert size (Supplemental Table S1).
Moreover, coverage tables and a variant call file for single-
and multiple-nucleotide variants, including number and
percentage of variant alleles, are provided. For TMB esti-
mation, variants are classified as somatic or germline by
using bioinformatical approaches, which make use of
various databases [including Catalogue of Somatic Muta-
tions in Cancer (COSMIC), The Genome Aggregation
Database (gnomAD), and 1000 genomes project] and take
into account the variant allele frequencies (VAFs) of sur-
rounding germline variants. For TMB calculation, somatic
SNVs with a VAF >5% are included. Hotspot mutations are
excluded to avoid overestimation of TMB, because the gene
panel is biased toward frequently mutated genomic regions
(cancer-related genes).
An in-house developed user interface was used for variant
annotation, variant filtering, and data visualization.36 Vari-
ants were filtered by excluding the following: i) variants not
overlapping with exons and splice site regions (8/þ8), ii)
synonymous variants, unless located in a splice site region,
and iii) variants present with a frequency >0.1% in the
control population represented in The Exome Aggregation759
Kroeze et alConsortium (ExAC) version 0.2. For tailored reporting
purposes, virtual gene panels were defined per tumor type in
close collaboration with the clinicians. For lung cancer, a
panel of 15 genes was composed (Supplemental Table S3).
After filtering, all remaining variants in the gene panel were
manually inspected and curated. A laboratory-developed
bioinformatic pipeline was used to analyze the unique
coverage and the presence of amplifications, as described
previously.37 For analyses of gene amplifications, the
coverage of each region in the tumor sample was normal-
ized using the median sequencing depth of all regions in the
sample. Subsequently, a relative coverage score was
calculated by dividing the normalized coverage of each re-
gion through the mean normalized coverage of this same
region in a set of 11 normal control samples.Evaluation of the Assay Performance
By analyzing formalin-fixed, paraffin-embedded and cyto-
logic samples from our routine clinical practice, the per-
formance of the TSO500 assay for TMB measurement, MSI
analysis, variant calling, and CNV detection was deter-
mined. POLE-mutated and MSI-positive samples were used
as positive controls, whereas normal tissue samples were
used as negative controls for TMB analysis. Mutation
detection, CNV analysis, and MSI analysis were evaluated
by comparing the TSO500 results with results from our
routine diagnostic tests. For mutation detection and CNV
analysis, single-molecule molecular inversion probe
(smMIP)ebased NGS is used,37e39 and for MSI detection,
genescan fragment length analyses of five mononucleotide
markers (pentaplex PCR), immunohistochemistry of the
mismatch repair genes, and/or evaluation of 55 microsatel-
lite markers by smMIP-based NGS using mSINGS software
version 3.4 are used.39,40
The intralaboratory reproducibility of TMB and MSI
measurements was determined through analysis of the same
commercially available control sample, obtained from Ho-
rizon Dx (Cambridge, UK), in 10 runs. For multisite
reproducibility studies, a control panel of eight DNA sam-
ples was sent to 11 independent laboratories, consisting of
DNA derived from six cell lines, one formalin-fixed,
paraffin-embedded tissue sample, and the Horizon Dx
control.
To further assess the performance and robustness of TMB
analysis, TMB values were measured and compared under
different conditions. First, dilution series were performed to
determine the minimal amount of input DNA to reliably
measure TMB. In addition, DNA quality (using DIN scores)
was correlated with median exon coverage to determine a
minimal quality value for reliable variant calling and TMB
analysis. Dilution series made by mixing tumor DNA with
normal DNA from the same patient (to mimic different
percentages of neoplastic cells) were used to determine the
minimal tumor cell percentage.760Mutational Signature Analysis
To infer the contribution of the 49 mutational signatures
available atCOSMIC (Mutational Signatures version 3,https://
cancer.sanger.ac.uk/cosmic/signatures/SBS/, last accessed
December 2, 2019), all samples with a nonsynonymous
TMB >10 mut/Mb were selected. Next, all somatic
synonymous, nonsynonymous, and intronic SNVs with a
VAF >5% that were absent or reported in gnomAD three or
fewer times from each sample were extracted. Synonymous
and intronic variants were included in mutational signature
analysis (but not in nonsynonymous TMB) to increase the
number of mutations, which makes the signature analysis
more reliable. Samples that harbored <30 SNVs were
excluded for further analysis. For each sample, the mutation
spectrum, based on all 96 trinucleotide substitutions, and the
estimated contribution of each signature to the mutation
spectrum were determined using the R package
DeconstructSigs.41Results
Assay Performance and Reproducibility
The performance of the TSO500 assay was evaluated using
DNA from 45 previously tested tumor samples and 11
normal tissue controls (Figure 1). One sample, an 8-
yeareold tissue block, had a median unique exon
coverage of 40, which was below the predefined quality
criterion of a median unique exon coverage of 150, which
is considered essential for reliable calling of variants with a
VAF of >5% (on average, 7.5 unique reads containing the
variant). This sample was excluded for further analysis. For
the remaining 55 samples, the median unique exon
coverage, determined using UMIs, was 362 (range, 150 to
756) (Supplemental Table S1). The median nonunique
coverage was 1501 (range, 844 to 2114). The coverage of
all individual target regions was rather uniform; the median
unique coverage of all autosomal targets varied up to one
order of magnitude (Figure 2A).
All pathogenic somatic mutations (n Z 59) detected
using our routine diagnostics smMIP-based NGS anal-
ysis38,39 were also detected by the TSO500 assay (Figure 2B
and Supplemental Table S4). Two deliberately selected
exceptionally complex variants, a deletion of 45 nucleotides
and a duplication of 48 nucleotides in KIT (Supplemental
Table S4), were not called by the pipeline but were
clearly present in the data (Supplemental Figure S1). Other
large insertions/deletions were correctly called, including a
30-nucleotide deletion in TP53 and a 26-nucleotide deletion
in MET. All known amplifications could be detected using
the TSO500 assay (Figure 2C and Supplemental Table S5).
All seven MSI-positive samples had >30% (median, 64%;
range, 34% to 80%) unstable microsatellite (MS) sites,
whereas all negative samples had <20% unstable MS sites
(median, 7%; range, 0% to 16%) (Figure 2D andjmd.amjpathol.org - The Journal of Molecular Diagnostics
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762are classified as MSI positive; samples with <15% unstable
microsatellite loci are classified as MS stable; and for
samples with 15% to 30% unstable microsatellites, immu-
nohistochemistry of mismatch repair proteins and/or pen-
taplex PCR will be used to clarify the MSI status.
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alysis. AeC: Three TMB-high tumor samples were diluted with normal tissue
s are indicated in green. Predicted somatic variants are shown in blue, with
t blue indicating variants with a VAF <20% in the original tumor sample. A
N) 37 (A) and UPN27 (B)] showed a clear decrease in TMB values, due to the
a sample (UPN51) with a rather stable TMB. Two groups of somatic variants
cates VAF threshold for TMB analysis. Ref, reference.
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Optimization of TMB Assessmenttumors with a POLE mutation, and 34 tumor samples
without MSI or a POLE mutation (16 lung cancer samples
and 18 samples of other tumor types) (Figure 2E and
Supplemental Table S1) were analyzed using the accom-
panying software. On average, per sample, 78% of detected
somatic mutations were nonsynonymous. The correlation
between total TMB (including synonymous and non-
synonymous variants) and nonsynonymous TMB was
strong (R Z 0.994) (Supplemental Figure S2). Non-
synonymous TMB values (mut/Mb) are further used in this
study and referred to as TMB. Sequencing of normal tissue
samples revealed a low background TMB value (median, 1
mut/Mb; range, 0 to 3.9 mut/Mb). MSI-positive samples
(median, 76 mut/Mb; range, 20 to 402 mut/Mb) and samples
with a POLE mutation (median, 122 mut/Mb; range, 111 to
292 mut/Mb) had consistently high TMB values. In the
other 34 tumor samples, a wide range of TMB values was
observed (median, 5.5 mut/Mb; range, 0 to 266 mut/Mb).
The three outlier high TMB values in this group were two
melanoma and one bladder cancer sample.
Intralaboratory reproducibility of the assay was assessed
using a control sample that was included in 10 sequencing
runs. Both MSI and TMB values were reproducible (MSI:
median, 71% unstable sites; SD, 3%; TMB: median, 245
mut/Mb; SD, 9.8 mut/Mb) (Figure 2, F and G). Interlabor-
atory reproducibility was assessed by analyzing eight sam-
ples at 11 independent laboratories. The MSI and TMB
results were consistent (Figure 2, F and G), indicating that
the assay is robust and the data analysis is highly
reproducible.
DNA Quantity, DNA Quality, and Tumor Cell Percentage
May Influence TMB Assessment
Subsequently, it was analyzed whether the DNA quality and
quantity can affect the TMB value. A positive correlation
was observed for both DNA quality and DNA input amount
with median unique exon coverage (both P < 0.0001)
(Supplemental Figure S3). To test whether DNA quality and
quantity affect TMB analysis, one high-quality (DIN, 4.2)
sample and one low-quality (DIN, 2.5) sample with a high
TMB were analyzed using different DNA input amounts (in
triplicate). The high DNA quality sample, an MSI-positive
sample with 80% tumor cells, showed highly reproducible
TMB values, even at the lowest tested DNA input amount
(11 ng) (Figure 3A). The low DNA quality sample, a POLE-
mutated sample with 30% tumor cells, showed stable TMB
results at DNA inputs of 40, 18, and 14 ng (Figure 3B).
However, at the lowest tested DNA input amount (9 ng), the
median exon coverage decreased to 57, which was accom-
panied by a decrease in TMB value. A similar DNA input
range was performed using sample UPN49 with a TMB of
10.2 mut/Mb (70% tumor cells and a low DNA quality:
DIN, 2.1), which showed stable TMB results using 40 and
20 ng DNA input and a little deviation when using 15 and
10 ng because of a decrease in the region that was takingThe Journal of Molecular Diagnostics - jmd.amjpathol.orginto account for TMB calculation (Supplemental Figure S4).
In conclusion, these experiments indicate that 20 ng of
DNA, an equivalent of 3000 cells, seems to be sufficient for
reliable TMB measurement, even in samples with a rather
poor DNA quality. This amount is available for the vast
majority of clinical specimens, even in case of small
biopsies or cytologic samples. Of note, when using low
DNA input amounts, the median unique exon coverage
decreases below the threshold of 150, whereas the median
nonunique exon coverage is still high (>900), indicating
the presence of many duplicate reads. This highlights the
importance of using UMIs to prevent overinterpreting the
sequencing data.
To determine the minimal tumor cell percentage to reli-
ably measure TMB, a dilution series was performed using
three samples with a high TMB and the matched normal
DNA from these patients (Figure 4). The tumor cell per-
centages of the original samples were estimated by a
pathologist. After sequencing, the actual tumor cell per-
centages of the original samples and subsequent dilutions
were determined using VAFs of three different mutations
(Supplemental Figure S5). When decreasing the tumor cell
percentage, the VAFs of all somatic variants will decrease.
However, as long as all variants (mut) still have a VAF
above the cutoff of 5% (as used in the TMB analysis soft-
ware) and the panel size is equal (Mb), the TMB (mut/Mb)
will stay the same. Of interest, with decreasing tumor cell
percentages, a marked decrease in TMB in two MSI-
positive samples was observed (Figure 4, A and B). The
VAFs of the somatic variants in these samples are hetero-
geneous, probably because of the underlying deficiency in
DNA repair (Supplemental Figure S6). When the tumor cell
percentage decreases, the VAF of some of these somatic
variants decreases below the cutoff of 5% used in the TMB
analysis software, leading to a decrease in TMB value. In a
melanoma sample with high TMB due to UV-induced
damage (as verified by its mutational signature; see
below), the TMB value remained stable in samples with
52% and 25% tumor cells (Figure 4C), but a slight decrease
in TMB was observed at 17% tumor cells. This decrease in
TMB is likely caused by chromosomal instability
(Supplemental Figure S6). When one of the chromosomes
of a chromosome pair is duplicated, the variants on the
noncopied chromosome will have a lower VAF than vari-
ants on the copied chromosome and variants on chromo-
some pairs not affected by instability. Consequently, these
variants more easily decrease below a VAF of 5% when
decreasing the tumor cell percentage. Therefore, in samples
with chromosomal instability, a tumor cell percentage of at
least 20% seems to be required (Supplemental Figure S7). In
the two samples with a defect in DNA repair (Figure 4, A
and B), 20% tumor cells still result in high TMB values
(>40 mut/Mb). Therefore, it is concluded that a tumor cell
percentage of at least 20% is required to minimize variations
in TMB values induced by chromosomal instability or
tumor heterogeneity.763
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Figure 5 Mutational signature analysis. The
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logue of Somatic Mutations in Cancer (COSMIC)
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Optimization of TMB Assessmentmore main mutational processes (Figure 5). After refitting of
the mutation spectrum of each sample to the 49 described
mutational signatures, signatures 10a and 10b, known to be
associated with POLE mutations, emerged as the main
mutational process in the three samples with a pathogenic
somatic mutation in the exonuclease domain of POLE
(UPN12, UPN40, and UPN43) (Figure 5 and Supplemental
Figure S8A). Moreover, the signatures for UPN43 indicated
an additional role for mismatch repair deficiency (Figure 5
and Supplemental Figure S8C). In all seven MSI-positive
tumors, the mutation spectrum can primarily be explained
by signatures that are associated with microsatellite insta-
bility (signatures 6, 15, 20, 21, and 26) (Figure 5 and
Supplemental Figure S8B). In four other samples, including
the two samples with the highest TMB without MSI or a
pathogenic POLE mutation (UPN19: 56 mut/Mb; and
UPN51: 266 mut/Mb) (Figure 2E), the mutation spectrum
showed a high contribution of signature 7, indicating
exposure to UV light as the main mutational process in these
tumors (Figure 5 and Supplemental Figure S8D). All four
tumors were melanomas.
In two samples (UPN50 and UPN51), a variant in the
POLE exonuclease domain (p.Val411Met and p.Pro418Ser)
was identified. No literature is available that proves the
pathogenicity of these variants. The valine on position 411
is a well-known hotspot location for POLE mutations that
lead to a POLE signature; however, in UPN50, the valine is
substituted by a methionine, whereas the known pathogenic
mutation is a substitution by leucine. Although the TMB in
both samples was extremely high (UPN50: 402 mut/Mb;
and UPN51: 266 mut/Mb), refitting of the mutational sig-
natures did not show a main contribution of POLE to the
mutational process, suggesting that most of the mutations
are caused by other mechanisms (UV exposure in UPN51
and MSI in UPN50) (Figure 5). This indicates that both
POLE mutations may be passenger mutations or late path-
ogenic events that barely contributed to the mutational
signature in these samples.
Comprehensive Analysis of a Consecutive Series of
Lung Tumors
To evaluate the applicability of the TSO500 assay in clinical
practice, a consecutive series of 58 lung tumor samples
received for diagnostic evaluation was tested (Supplemental
Table S6). All cytologic samples (n Z 18), tissue biopsies
(nZ 21), and surgical resections (nZ 19) were sequenced
successfully. Detailed evaluation of somatic mutations was
performed for a panel of 15 genes (Supplemental Table S3)
that are commonly mutated in lung cancer and/or potentially
actionable. One or more mutations were detected within
these genes in 91% of the tumors (Figure 6 and
Supplemental Table S6). The most frequently mutated gene
was TP53 (69%), followed by KEAP1 (28%), KRAS (24%),
and STK11 (16%). EGFR (7%) and KRAS mutations were
exclusively found in adenocarcinoma samples. Because theThe Journal of Molecular Diagnostics - jmd.amjpathol.orgfull coding region of each gene is covered, it was also
possible to detect potentially clinically relevant mutations in
regions of BRAF (p.Glu501Gly) and PIK3CA (p.Arg88Gln,
p.Arg93Trp, p.Lys111Asn, and p.Gly118Asp) that are not
frequently mutated, and therefore not present in most
commercially available targeted NGS panels. In patient
UPN73, who previously tested positive for an activating
EGFR mutation, leading to treatment with erlotinib fol-
lowed by osimertinib, a less common PIK3CA mutation
(p.Gly118Asp) could most likely explain the acquired
EGFR tyrosine kinase inhibitor resistance. ALK, ROS1, and
RET translocations were assessed using standard immuno-
histochemistry and/or fluorescence in situ hybridization
techniques. One ALK and two RET translocations were
detected in this cohort (Figure 6).
The most effective cutoff for a high TMB is still under
investigation in clinical trials, but is set at 10 mut/Mb for
lung cancer in the Checkmate 568.19 When applying this
threshold, 45% of the samples had a high TMB. Refitting of
the mutational signatures of all samples with 30 somatic
mutations (n Z 16) revealed nine samples (56%) with a
large contribution of signature 4, which is highly associated
with tobacco smoking (Figure 6 and Supplemental
Figure S9). Four samples with a high TMB showed that
the mutation spectrum was in part explained by mutational
signatures associated with increased activity of the activa-
tion induced deaminase/apolipoprotein B mRNA editing
enzyme, catalytic polypeptide-like (AID/APOBEC) family
of cytidine deaminases (signatures 2 and 13) (Figure 6 and
Supplemental Figure S9). Of interest, although none of the
investigated lung cancer samples in this diagnostic series
showed MSI according to TSO500 analysis, refitting of the
mutation spectrum of UPN95 showed relatively high
contribution of signature 6, which is associated with
mismatch repair deficiency (Supplemental Figure S9). This
sample did not meet our minimum acceptance criteria of
30% tumor cells for reliable MSI analysis (25% tumor
cells and 10% unstable MS sites) (Supplemental Table S6).
Subsequent analysis of another sample of this tumor, con-
taining 50% tumor cells, resulted in 22% unstable MS sites.
Indeed, smMIP-based NGS analysis and pentaplex PCR
both confirmed a (subtle) unstable pattern.
PD-L1 positivity [antibody 22C3 pharmDx (Agilent
Technologies) or E1L3N (Cell Signaling Technology,
Danvers, MA)] was detected in 43% of the samples. No
correlation could be observed between PD-L1 positivity and
a high TMB (P Z 0.2276) (Supplemental Figure S10),
indicating that these markers are independent.Discussion
To assess whether multiple biomarkers can be determined in
a single assay and to what extent different parameters may
influence TMB values, a commercially available 523-gene
panel, TSO500, and its accompanying software were765
Kroeze et alevaluated. DNA isolated from a range of sample types
(formalin-fixed, paraffin-embedded tissue blocks, cytologic
material embedded in agar, and cytologic material stained
with Giemsa or Papanicolaou) was successfully sequenced.
All previously determined mutations, amplifications, and
MSI present in these samples were detected, although two
exceptionally large insertions/deletions required visual in-
spection of the aligned reads. CNV detection is increasingly
becoming integrated in NGS panels.37 An advantage of
using TSO500 for CNV detection is that all genes are
completely covered, which makes CNV detection more
reliable compared with NGS panels in which only a few
regions of a gene are analyzed.
The TSO500 is able to determine TMB values without
the need for matched normal DNA by using bioinformatic
approaches to discriminate between germline and somatic
variants. This a major advantage because obtaining and
sequencing DNA from normal tissue is not always feasible,
is rather expensive, and may lead to ethical issues con-
cerning the risk to detect pathogenic germline variants. On
the other hand, by using this bioinformatic approach, some
variants may be incorrectly labeled as germline or somatic,
which might slightly affect the TMB value. During assay
evaluation, TMB values were observed to be uniformly low
in normal tissue samples and high in samples with MSI or a
POLE mutation. High interlaboratory reproducibility in MSI
and TMB values was shown. Furthermore, a recent publi-
cation shows good agreement between TSO500 and whole
exome sequencingebased TMB assessment.42 These results
demonstrate that the assay performs well, even without
using matched normal DNA.
As TMB is an emerging biomarker for stratification of
patients for immunotherapy, it is essential to understand the
reliability of the TMB values assessed under different con-
ditions. Recent publications highlight the importance of panel
size, panel content, and bioinformatic parameters for reliable
panel-based TMB estimation.29,43e45 No comprehensive ex-
periments have been performed thus far to determine the
effect of DNA quality, DNA quantity, and tumor cell per-
centage on TMB assessment. The analyses in this manuscript
show that both a low DNA input amount and poor DNA
quality can lead to a decrease in the median unique exon
coverage and consequently the measured TMB value. On the
basis of the findings presented herein, 20 ng of DNA is
considered to be sufficient for reliable TMB evaluation, even
in relatively poor-quality samples. Sufficient coverage (me-
dian unique exon coverage of150) could be obtained for all
DNA samples with a DIN score >2. Furthermore, the TMB
value may be influenced by the tumor cell percentage in
heterogeneous tumors (eg, MSI-positive tumors) and tumors
with a high degree of chromosomal instability. The TMB in
heterogeneous tumors may also differ depending on the site
where the biopsy is taken, as described by Kazdal et al.42
Overall, it is concluded that for TSO500 analyses, a tumor
cell percentage of 20% is required for TMB analysis,
because at 20% tumor cells, somatic mutations on the766noncopied chromosome in samples with chromosomal
instability (up to four chromosome copies) still have a VAF
>5% (Supplemental Figure S7), and samples with defects in
DNA repair (Figure 4, A and B) still have high TMB values
(>40 mut/Mb).
A benefit of using a large gene panel is that mutational
signature analysis can be performed in samples with suffi-
cient mutations. In most samples with 30 presumed so-
matic SNVs, a mutational signature could be defined that
matched with the known underlying mutational mechanism
(eg, DNA mismatch repair deficiency or hypermutation due
to a POLE mutation) or corresponded with the tissue of
origin (UV signature in melanoma samples or tobacco
smoking in lung cancer). More importantly, these muta-
tional signatures may support the differential diagnosis in
cases of metastasis of unknown primary origin, allow the
classification of potential pathogenic variants in DNA repair
genes, and may determine the presence of mutational pro-
cesses important for tumorigenesis and therapy choice that
are not supported by specific somatic variants, but are, for
example, caused by promoter hypermethylation.46
After evaluation of the assay performance, the applica-
bility of the assay in daily practice was confirmed in a
consecutive series of 58 lung cancer specimens that required
molecular diagnostic evaluation. The frequency of detected
genetic aberrations in the investigated cohort might slightly
differ compared with other cohorts because this is a mixed
cohort of adenocarcinoma and squamous cell carcinoma
samples, which also contains stage I and II nonesmall-cell
lung cancer patients. In addition, a selected population of
lung cancer patients from surrounding hospitals is referred
to our center, leading to some bias in this cohort. In the
tested cohort, a TMB 10 mut/Mb was found in 45% of the
lung cancer samples, which is consistent with previous re-
ports.19 Refitting of the mutational signatures revealed that
more than half (9/16) of these TMB-high samples showed a
mutational signature associated with smoking. In addition,
four TMB-high samples showed mutational signatures
associated with increased activity of the AID/APOBEC
protein family. These proteins play an important role in
mRNA editing by deaminating cytosines; however, when
misregulated, this may result in multiple mutations.47
Recent studies showed that nonesmall-cell lung cancer
patients with a high TMB associated with an AID/APOBEC
mutational signature showed a strong correlation with
response to immunotherapy.48,49 Finally, in one biopsy
sample, the mutation spectrum showed high similarity with
signature 6. Of interest, the MSI status in this sample could
not be determined because the tumor cell percentage (25%)
was below the predefined cutoff of 30%. The result of this
mutational signature analysis motivated us to sequence a
resection sample of this patient containing 50% tumor cells,
which confirmed an intermediate level of microsatellite
instability (22% unstable MS sites) and thereby highlights
the added value of performing mutational signature ana-
lyses. In line with previous reports, no correlation wasjmd.amjpathol.org - The Journal of Molecular Diagnostics
Optimization of TMB Assessmentobserved between PD-L1 positivity and a high TMB.19,32,50
As more studies emerge demonstrating that PD-L1, MSI,
and TMB are all important markers to predict response to
immunotherapy in lung cancer, it is becoming increasingly
important to screen for all three biomarkers.19,50e52
In conclusion, the use of a large pan-cancer panel, like
TSO500, allows comprehensive and simultaneous assess-
ment of SNVs, multiple-nucleotide variants, CNVs, TMB,
and MSI in a single assay. Additional benefits of using a
large gene panel are that both accepted and emerging bio-
markers can be measured and that mutational signatures can
be determined in tumors with a sufficient number of muta-
tions. The current article shows that for reliable TMB
evaluation, it is important to consider DNA quality, DNA
quantity, and the tumor cell percentage of a sample. A low
DNA input amount and/or quality can result in a low me-
dian unique exon coverage, which can affect the TMB
estimation. In samples with a low tumor cell percentage
(<20%) that harbor many subclonal mutations or show a
high level of genetic heterogeneity, TMB values may be
underestimated because the frequency of some variants is
below the VAF threshold of 5% and consequently these
variants are not included in the TMB calculation. We,
therefore, recommend that evaluations of assays for TMB
assessment include a definition of minimum acceptance
criteria for DNA quality, DNA quantity, and tumor cell
percentage next to analysis of the reproducibility and cor-
relation with TMB values of other assays. Only after
rigorous evaluation of the used assay, TMB values can be
considered as a putative biomarker for immunotherapy
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